Exploring Treatment Approaches for Advanced Prostate Cancer
Panelists review four 4 clinical cases, discussing guideline-directed approaches to new and emerging treatment approaches in patients with hormone-sensitive and castration-resistant prostate cancer, as well as share sharing perspectives on key clinical trial data that may impact our decisions.
EP. 1: Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Overview
November 27th 2024Panelists discuss how metastatic castration-sensitive prostate cancer (mCSPC) is managed with a combination of androgen deprivation therapy, chemotherapy, and novel agents like such as abiraterone and enzalutamide, aiming to improve survival outcomes while addressing the disease's high metastatic burden.
EP. 2: Case 1: Metastatic Castration- Sensitive Prostate Cancer (mCSPC)
December 4th 2024Panelists discuss how the management of metastatic castration-sensitive prostate cancer involves a multidisciplinary approach, utilizing androgen deprivation therapy, chemotherapy, and novel agents to control disease progression and improve patient survival.
